Calabrese Consulting LLC’s Post

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 0-0% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 19-10%, urging caution on returns. 🚨🤔 3⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 97 - 68% promising exciting returns! 🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 34- 20% signaling less potential gains! 5⃣ Bharat Highways InvIT IPO, priced at 100, commands a stellar GMP of 0-0% promising exciting returns! 🌐🚀 6⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 15 promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- it is only for educational purposes

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 0-0% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 19-10%, urging caution on returns. 🚨🤔 3⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 97 - 68% promising exciting returns! 🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 34- 20% signaling less potential gains! 5⃣ Bharat Highways InvIT IPO, priced at 100, commands a stellar GMP of 0-0% promising exciting returns! 🌐🚀 6⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 15 promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- it is only for educational purposes

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 0-0% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 9-5%, urging caution on returns. 🚨🤔 3⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 129 - 91% promising exciting returns! 🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 92- 54% signaling less potential gains! 5⃣ Bharat Highways InvIT IPO, priced at 100, commands a stellar GMP of 0-0% promising exciting returns! 🌐🚀 6⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 15 promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- it is only educational purposes.

As we enter 2024, private equity investors are poised for a dynamic year of mergers and acquisitions in the realm of "outsourced pharma services." Despite the seemingly unglamorous label, the sector has captured the attention of PE players, especially in Europe. With a robust pharma and life sciences sector and several PE-owned assets maturing, industry experts predict a surge in M&A activities. Medical communications agencies, specializing in services to commercialize new drugs, are taking centre stage. Notable players, such as UK-based Avalere Health (formerly Fishawack Health), are expected to make their way to the market in 2024, adding to the lineup of PE-owned businesses in this space. Even in the face of challenges experienced by debt markets in 2023, PE owned assets in the medical communications sector have displayed impressive growth, propelled by strategic initiatives. The sector's resilience and strategic positioning continue to make it an attractive destination for private equity investments. #PrivateEquity #PharmaServices #PEInsights

The healthcare industry is on the move, and mergers and acquisitions are playing a central role. Take the recent acquisition of BioMatrix Holdings by Frazier Healthcare Partners. This deal highlights a key trend: consolidation. Why consolidate? By joining forces, healthcare providers like BioMatrix can: • Expand their reach: BioMatrix plans to leverage this acquisition to open new locations and serve a wider patient base. • Offer a broader range of services: Acquisitions can help companies like BioMatrix add new therapies to their service offerings, catering to a wider range of patient needs. • Gain a competitive edge: Consolidation allows healthcare providers to benefit from economies of scale, potentially reducing costs and improving their competitive positioning in the market. Don't miss out on other valuable insights in the healthcare industry. Read the full report here: https://lnkd.in/g32BJwAH #healthcare #manda #mergersandacquisitions #investmentbanking

The first quarter of 2024 witnessed mergers and acquisitions positively shaping the industry's trajectory. These deals reflect the current trend in Big Pharma: snapping up small late-stage biotechs. In parallel, the IPO market showcased more promise, underscoring the industry's resilience and investors' confidence in innovative biotech ventures. Read more in Fierce Biotech: https://bit.ly/3Ja42Si #MergersAndAcquisitions #PharmaceuticalIndustry #Innovation #Healthcare #IPOs

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 6-2% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 0-0%, urging caution on returns. 🚨🤔 3⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 10 promising exciting returns! 🌐🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 0- 0% signaling less potential gains! 5⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 71 - 50% promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- It is only for educational purposes.

📢 GMP MAINBOARD IPO Juniper Hotels: Nil IPO Price: 360/- GPT Healthcare: 10/- (5.38%) IPO Price: 186/- Exicon Tele: 130/- (91.55%) IPO Price: 142/- Platinum Ind: 90/- (52.63%) IPO Price: 171/- Mukka Proteins: 15/- IPO Price: 28/- (Expected) (As Heard from Various Brokers or Social Media)… Stay connected 🤝 with us... ✅Follow @ GTA Finserv for more such updates on upcoming IPOs... Please note that whatever GMPs I am posting are just for knowledge purpose. We do not support or execute grey market trades. #GMP #IPO #IPOALERT #SME $INDIAIPO.P $NIFTY50.NSE

Nephro Care IPO Shows 200% Premium, Listing Caution The overwhelming response to the Nephro Care IPO underscores investor confidence in the healthcare sector and SME offerings on the NSE Emerge platform   https://shorturl.at/pzBJP #NephroCareIPO #NephroCare #DeepakParekh #IPO #NationalStockExchange

Are you planning to take your life sciences company public? This is a big move, one that demands intensive planning and preparation. You need to perform all the usual due diligence of a standard IPO, combined with extra oversight to make sure you're meeting all the regulatory requirements for your field. In our guide, we lay out everything you need to know, step by step. Check it out and make sure you're prepared: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic